Rankings
▼
Calendar
MESO FY 2023 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
-26.5% YoY
Gross Profit
-$47M
-632.2% margin
Operating Income
-$69M
-923.7% margin
Net Income
-$82M
-1091.7% margin
EPS (Diluted)
$-0.98
Cash Flow
Operating Cash Flow
-$63M
Free Cash Flow
-$64M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$669M
Total Liabilities
$168M
Stockholders' Equity
$502M
Cash & Equivalents
$71M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$10M
-26.5%
Gross Profit
-$47M
-$53M
+11.1%
Operating Income
-$69M
-$81M
+14.0%
Net Income
-$82M
-$91M
+10.4%
← Q4 2022
All Quarters
Q1 2023 →